title: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.
authors.affiliation: Department of Medical Oncology, Charing Cross Hospital, London, U.K.
authors.forename: E S
authors.initials: ES
authors.lastname: Newlands
authors.forename: M F
authors.initials: MF
authors.lastname: Stevens
authors.forename: S R
authors.initials: SR
authors.lastname: Wedge
authors.forename: R T
authors.initials: RT
authors.lastname: Wheelhouse
authors.forename: C
authors.initials: C
authors.lastname: Brock
mesh_terms: D000328:Adult; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry / Q000494:pharmacology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000188:drug therapy; D000077204:Temozolomide; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide